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ABSTRACT
Elongating axons require a host of macromolecules for outgrowth. The importance of lipid,
protein, and general RNA synthesis for initial axonal growth has been previously investigated,
but the role of rRNA synthesis and ribosome production in axonal morphogenesis remains
unclear. Therefore, rat hippocampal neurons were cultured and transfected with shRNA against
either TIF-IA (the activator of RNA polymerase I) or RPS6 (a small ribosomal subunit
component) to determine the effects of impaired de novo ribosome synthesis on axonal
development during the first three days after plating. Our data show that shRPS6 weakly
inhibited total axon length, but not longest axon path or number of axonal branches; shTIF-IA
showed no significant inhibitory effect in all three parameters. Thus, these results indicate that
the pre-existing ribosome supply was at least temporarily sufficient for growth during this initial
phase of axonal development.

BACKGROUND
Known as the cellular “ribosome factory”, the nucleolus is the dynamic sub-nuclear structure in
all eukaryotic cells. The nucleolus is composed of RNA and proteins grouped around specific
chromosomal regions called nucleolar organizing regions (NORs), which are comprised of
numerous tandem repeats of the ribosomal DNA (rDNA) coding for ribosomal RNA (rRNA) [1].
Primarily involved in ribosomal biogenesis, the nucleolus directs the synthesis and processing of
rRNAs before assembling them together with ribosomal proteins (RPs) imported from the
cytoplasm to create the large 60S and small 40S ribosomal subunits found in eukaryotic
ribosomes [2]. Following production in the nucleolus and maturation in the nucleus, the large
60S and small 40S ribosomal subunits are transported out of the nucleus and into the cytoplasm,
where they then combine with processed mRNA transcripts. Specifically, the 40S subunit first
binds with translation initiation factors and an mRNA transcript, which then facilitates the
binding of the 60S subunit [3]. This constitutes the formation of a fully functional ribosome,
which is the cellular translation machinery that is responsible for catalyzing protein synthesis [4].
Given the multitude of proteins required for normal cell function and survival, the role of
ribosomes as the cellular translation machinery makes them indispensable for cellular growth. As
such, the critically important roles that the nucleolus plays in ribosomal biogenesis can have a
drastic impact on the capacity of the cell to grow [2]. Additionally, the nucleolus has been
attributed many roles in the maintenance of cellular homeostasis and its dysfunction has been
linked to various pathologies [5]. While in eukaryotes RNA polymerase (pol) II is responsible
for the transcription of genes encoding proteins, RNA pol I is responsible for the transcription of
rRNA-encoding genes in the nucleolus [6, 37]; therefore, RNA pol I transcriptional activity
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serves as an important regulator of ribosomal biogenesis and thus enables protein synthesis and
cellular growth [7]. Activity of RNA pol I, in turn, is closely regulated by multiple biochemical
pathways to adjust ribosomal biogenesis according to cellular demands [7]. Generally speaking,
conditions that are detrimental to cell growth (such as lack of growth factors or inhibition of
protein synthesis) result in a down-regulation of RNA pol I [30]. Conversely, RNA pol I is upregulated to increase rRNA synthesis by the presence of neurotrophic factors, mitogenic signals,
and favorable environmental conditions. Specifically, as one of its final targets, the extracellular
signal-related kinase (ERK) pathway phosphorylates transcription initiation factor 1A (TIF-IA),
which promotes the association of RNA pol I with rDNA gene promoters in rRNA synthesis
[31]. In sum, RNA pol I tightly links cellular growth to changes in environmental conditions by
determining the level of ribosome production [30–32].
Given its role in the regulation of RNA pol I activity, TIF-IA was selected as a target for
shRNA-mediated inhibition in this experiment. More than two decades ago, TIF-IA was found to
control the growth-dependent regulation of rRNA synthesis in mice by responding to
extracellular signals [38]. More broadly, it was found that TIF-IA is the mammalian functional
homolog of the yeast factor Rrn3p, both of which “activate” RNA pol I, making it competent for
transcription initiation [39, 40]. Specifically, this activation is achieved by direct association of
TIF-IA with RNA pol I to form a transcriptionally active holoenzyme that is able to bind to the
rDNA promoter and initiate transcription in the presence of auxiliary cofactors, including the
selectivity factor SL-1 (also called TIF-IB) and upstream binding factor (UBF) [38]. Different
signaling pathways are believed to be responsible for the ability of TIF-IA to respond to
extracellular signals and regulate cell growth and proliferation, especially via ERK- and mTOR
(mammalian target of rapamycin)-mediated modulation of the phosphorylation state of TIF-IA
[31, 32]. Further regulation includes the action of the Akt pathway, which stabilizes TIF-IA,
triggers its nucleolar translocation, and augments its interaction with RNA pol I [41]. Also, in
connection with TIF-IA, this project takes advantage of the nucleolar phosphoprotein B23 (also
known as numatrin, nucleophosmin, and NPM1) [18]. Given its localization in the nucleolus and
its association with pre-ribosomal particles, B23 is an established nucleolar marker [18, 24]. As
such, B23 dispersion serves as an indicator of nucleolar disruption and, thus, successful shTIFIA inhibition of RNA pol I activity. In sum, as the primary regulator of RNA pol I-driven rDNA
transcription, TIF-IA activity is of obvious importance for ribosomal biogenesis.
Despite shared transcriptional and translational processes underlying general cellular growth,
different cells types demonstrate different patterns of development based on their specifically
determined functions. Neurons are post-mitotic cells that no longer divide but continue to grow.
Specifically, this growth consists of the development and elongation of neurites, including axons
and dendrites. This neurite development – specifically with hippocampal neuron cultures – has
been thoroughly studied in vitro, elucidating a process that can be broken down into five
characteristic stages: within hours of adhering to the substrate, Stage 1 cells develop many small,
motile, peripheral extensions known as lamellipodia; during Stage 2 the lamellipodia extend and
become minor processes after about one day in vitro (DIV 1); within DIV 1-2, Stage 3 sees the
particularly pronounced outgrowth of a single minor process, which forms a single major
process. This major process continues its rapid growth, becoming a clearly identifiable axon
between DIV 3-7. Significant dendritic outgrowth begins during Stage 4 around DIV 4, but the
dendrites remain morphologically and biochemically distinct from the singular axon. [23]
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However, such extensive morphological development of neurons involves a marked increase in
cell volume and surface area. These increases necessarily require various macromolecules to
support membranous and cytoskeletal expansions. An important study by Jareb and Banker
demonstrated how axonal growth is differentially affected by inhibition of the supply of these
macromolecules in rat hippocampal neurons at 18 hours after plating: disruption of the supply of
Golgi-derived vesicles by treatment with brefeldin A inhibited axonal growth within one hour,
showing the importance of lipid membrane components; cycloheximide (CHX)-mediated
disruption of protein synthesis also significantly inhibited axonal growth, but only after six
hours; and actinomycin D, a general RNA synthesis inhibitor, also inhibited axonal growth after
nine hours [42] (Figure 1). The selected timeframe of about 18-30 hours after plating roughly
corresponds to the aforementioned Stage 3 (DIV 1-2) in which robust axon growth begins [23].
Therefore, the supply of lipids, RNA, and proteins to the developing axon appear to be crucial
for growth during this early phase of elongation. Of particular interest for this work is the
necessity of protein synthesis for axonal growth, given that ribosomal biogenesis ultimately
serves to produce ribosomes capable of fulfilling the cell’s translational needs.

Given the importance of protein synthesis for axonal development, proper regulation becomes
crucial. The protein kinase mTOR has been identified as a key regulator of cellular growth via its
regulation of protein synthesis and the translation machinery [29]. In particular, PI3K
(phosphatidylinositol 3-kinase)/mTOR signaling regulates TIF-IA activity [7,32]. In addition to
affecting numerous other downstream targets, the role of mTOR in recruitment of ribosomes to
mRNA has been linked to its phosphorylation of RPS6, a functional component of ribosomes
[12]. The aforementioned interlacing signaling pathways provide for careful control of protein
synthesis. Nevertheless, the location of this protein synthesis within the neuron has been debated
for decades. While dendrites have long been known to contain ribosomes and undergo local
protein synthesis, the same was not thought to occur in axons [28]. In fact, ribosomes were
thought to be excluded from axons; it was believed that axoplasmic proteins were actually
produced in the cell body and slowly transported to their particular destination(s) in the axon [33,
and references contained therein]. However, a recently growing body of evidence has indicated
that axons also possess ribosomes and rely on local protein synthesis for growth and directional
responses [34 and references contained therein]. Indeed, studies have shown that ribosomes exist
within periaxoplasmic ribosomal plaques (PARPs) distributed across the length of the axon, and
that myosin and kinesin motor proteins play a role in this ribosomal trafficking and distribution
[43]. Local protein synthesis in axons is thought to be necessary for expedient control of the
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local proteome, including correct localization of axonal proteins, allowing the growth cone to
quickly respond to environmental stimuli, and to avoid macromolecular crowding caused by
protein storage [35 and references contained therein]. Interestingly, it has been shown that
neurite outgrowth is resistant to incomplete inhibition of protein synthesis by CHX; this
resistance is attributed to a concurrent decrease in the rate of protein degradation that parallels
the decrease in protein synthesis [36].
Observations of nucleolar morphology in different regions of the nervous system have provided
evidence that increased ribosomal biogenesis – as indicated by dynamic nucleolar activity and
reorganization – is directly linked to neuronal growth [8]. Indeed, Dr. Hetman’s lab has
demonstrated that experimental knockdown of TIF-IA – a coactivator of RNA pol I – in rat
hippocampal neuron cultures inhibits brain-derived neurotrophic factor-induced (BDNF) neurite
growth, although not overall protein synthesis [7]. These results demonstrate the dependence of
nervous system development on the nucleolar transcriptional activity of RNA pol I, indicating
the importance of the nucleolus for neural cell growth. Because general protein synthesis was not
reduced in experiments with cells from DIV 2-3, these morphogenetic requirements for neuritic
growth in this early phase of development cannot be accounted for simply in terms of changes in
overall capacity for translation. By contrast, when RNA pol I was inhibited on DIV 6-8,
translational capacity was clearly reduced [Slomnicki and Hetman, unpublished observations].
Stemming from this research on the role of RNA pol I in neurite outgrowth, the Hetman lab is
now investigating the role of ribosomal biogenesis in neurite outgrowth via short hairpin RNA
(shRNA) knockdown of TIF-IA and various ribosomal proteins, including RPS6, RPL4, and
RPS14. Currently unpublished data from Dr. Hetman’s lab has shown that shRNA-mediated
knockdown of TIF-IA, RPL4, RPS14, and RPS6 significantly reduced dendritic growth in later
stages from DIV 6-9; this indicates the importance of pol I activity and ribosomal biogenesis in
dendritic growth [Slomnicki et al. In preparation]. However, these experiments did not involve
axons, which, unlike dendrites, are uniquely neuronal structures; therefore, it remains to be tested
whether or not shRNA knockdown of TIF-IA and/or ribosomal proteins will similarly impact
axonal growth.
As integral components of functioning ribosomes, ribosomal proteins are important for protein
synthesis and, thus, cellular growth. For this experiment, RPS6 was selected as the ribosomal
target for shRNA knockdown to determine the effect that this would have on axonal growth.
RPS6 was discovered in 1974 in connection with liver regeneration [10]. RPS6 is a ribosomal
protein consisting of 249 amino acids, including five known phosphorylation sites – which are
evolutionarily conserved in metazoans – at clustered residues in the C-terminal region of the
protein: Ser235, Ser236, Ser240, Ser244, and Ser247 [11]. Since its discovery, RPS6 has been one of
the most extensively researched ribosomal proteins, largely due to the fact that it was the first
ribosomal protein to be known for its capacity for inducible phosphorylation [12]. In terms of its
canonical role as a ribosomal protein, RPS6 is a component of the small 40S subunit of
eukaryotic ribosomes; it is located at the interface of the 40S subunit with the 60S subunit, where
it interacts with initiation factors, mRNA, and tRNA [13]. As such, it appears that RPS6
functions in mRNA binding, and so phosphorylation of RPS6 may help to regulate translation
[12]. With respect to phosphorylation, RPS6 is included within the category of S6 kinase (S6K)
substrates [12]. As such, it was previously suggested that RPS6 phosphorylation may regulate
initiation of translation and inclusion of ribosomes in polysomes; however, experiments with
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RPS6P-/- knock-in mice liver cells (with phosphorylation prevented at all aforementioned serine
residues) have shown the same proportion of ribosome recruitment into polysomes as in the liver
cells of wild-type mice. Indeed, in comparison with the wild-type mice, protein synthesis levels
in the knock-in mice were actually higher, suggesting that RPS6 phosphorylation down-regulates
protein synthesis in at least liver cells [12]. Evidence shows that RPS6 phosphorylation plays
other key roles, such as regulating translation of 5’ terminal oligopyrimidine (TOP) mRNA
tracts. Additionally, elevated RPS6 levels were discovered in primary diffuse large B-cell nonHodgkin lymphoma samples with excessive cellular proliferation, whereas genetic treatment
with shRPS6 led to a reduction in cell proliferation [14]. Given the potential novel roles that
RPS6 may play, further investigation is needed to discern the mechanism by which RPS6
expression may regulate axon growth.

	
  
RESESARCH PROBLEM
Currently unpublished data from Dr. Hetman’s lab has shown that shRNA-mediated knockdown
of TIF-IA and various ribosomal proteins (RPL4, RPS14, and RPS6) significantly reduced
dendritic growth [Slomnicki et al. In preparation]. While working in Dr. Hetman’s lab during the
previous academic year, we sought to continue this line of research and investigate whether a
similar effect is observed in growth of axon. Because axons are a uniquely neuronal appendage,
the effects that such disruptive knockdowns have on axons are of particular importance: the
unique ability of axons to successfully elongate to great lengths underlies the structure and
connectivity of a healthy nervous system. Therefore, this project seeks to investigate the
importance of ribosomal biogenesis and nucleolar activity for axon development. In order to do
this, ribosomal biogenesis was partially inhibited via shRNA knockdown of RPS6, and nucleolar
function was disrupted by strong inhibition of RNA pol I activity via shTIF-IA knockdown.

EXPERIMENTAL PROCEDURES
The following antibodies and reagents were obtained from commercial sources:
reagents included BDNF (Alomone, Haifa, Israel) and Lipofectamine 2000 (Invitrogen,
Carlsbad, CA); primary antibodies included rabbit anti-GFP (MBL; 1/1000) and mouse antiB23/NPM1 (Sigma; 1/750); and secondary antibodies included Alexa Fluor 488 goat anti-rabbit
IgG (Invitrogen, 1/300) and Alexa Fluor 555 goat anti-mouse IgG (Invitrogen, 1/300).
Materials:

Back transformation allowed for the extraction of the desired pSUPER
plasmid vector (OligoEngine) from Escherichia coli bacteria: the cells were subjected to a
membrane dissolving chemical and centrifuged, and the resulting supernatant containing the less
dense plasmid DNA was collected. A plasmid mini-preparation kit (Qiagen) was then used to
chromatographically isolate the DNA, utilizing various buffers to remove contaminants such as
RNA, nucleases, and carbohydrates. Following workup, plasmid DNA sample purity was
determined using a NanoDrop spectrophotometer.
Plasmid Preparation:

Neuron Culture & Transfection: Hippocampal

neurons were isolated from newborn SpragueDawley rats (Harlan) at postnatal day zero (P0), as described previously [15]. Briefly,
hippocampi were dissected and digested using papain, followed by a trypsin inhibitor; the
hippocampi were then triturated in Basal Medium Eagle (BME) supplemented with 10% heatinactivated bovine calf serum (Hyclone). Finally, the hippocampal neurons were plated at a
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density of 0.2 × 106 per well in a 24-well plate in Neurobasal medium containing 2%-B27
nutrition supplement (Invitrogen), 1 mM L-glutamine, 100 units/mL penicillin, and 0.1 mg/mL
streptomycin. Cells were plated onto poly-D-lysine- and laminin-coated 12 mm diameter plastic
coverslips that were produced in the lab from the electron microscopy-grade myalar masks
(Electron Microscopy Sciences). Half of the media was changed every other day. At one day in
vitro (DIV 1) neurons were transiently cotransfected with expression plasmids for GFP (0.1 µg
of plasmid DNA/2 × 105 neurons) as a transfection marker, and either control Renilla luciferase
shRNA (shLuc), shTIF-IA, or shRPS6 (0.4 µg of plasmid DNA/2 × 105 neurons), using
Lipofectamine 2000 according to standard manufacturer protocol. On DIV 2 the cells were also
treated with either human recombinant BDNF (20 ng/mL) dissolved in the vehicle solution of
0.1% BSA/PBA, or the vehicle alone, for a further 24 hours, followed by fixing cells with 4%formaldehyde solution after immunostaining on DIV 3-4.
Immunostaining: All

cultured neurons were stained after 10-minute fixation in 4% PFA with 4%
sucrose, followed by washing with PBS. GFP staining was performed using primary rabbit antiGFP antibody (1/1000), followed by secondary Alexa Fluor 488 goat anti-rabbit IgG (1/300).
B23 staining was performed using primary mouse anti-B23/NPM1 antibody (1/750), followed by
secondary Alexa Fluor 555 goat anti-mouse IgG (1/300). In all cases, standard staining protocols
were followed. Following immunostaining, cells were counterstained with 2.5 µg/mL of the
DNA dye Hoechst 33258 in order to visualize nuclear morphology. After washing in PBS,
coverslips were mounted on coverslips in glycerol gelatin (Sigma) containing p-phenyldiamine
glycerol.
shRNA Construct Generation & Validation: Two

different shRPS6 constructs (designated as
“shRPS6.1” and “shRPS6.2”) and three different shTIF-IA constructs (used together, designated
as “shTIF-IA”) had been previously generated by analyzing each mRNA sequence using shRNA
design software (Ambion.com) and off-target prediction software (sonnhammer.sbc.su.se) as
previously described. As previously described, oligonucleotides were designed
(S6#1: 5'-gatccccgatgatgtccgccagtatgttcaagagacatactggcggacatcatcttttta-3';
S6#2: 5'-gatccccgattcagcgtcttgttactttcaagagaagtaacaagacgctgaatcttttta-3';
TIF-IA#1: 5’-gatccccgacttagagttgttgaagattcaagagatcttcaacaactctaagtctttttggaaa-3’;
TIF-IA#2: 5’-gatccccgcacagactgtcttccttattcaagagataaggaagacagtctgtgctttttggaaa-3’;
TIF-IA#3: 5’-gatccccgtgttctgctacaccatcattcaagagatgatggtgtagcagaacactttttggaaa-3’) together with
their complementary counterparts, annealed and sub-cloned into a pSUPER vector digested with
BglII and HindIII [26; Slomnicki et al. In preparation]. Within the shRPS6 experiment, the first
two groups consisted of the separated S6#1 (shRPS6.1) and S6#2 (shRPS6.2) sequences,
respectively. In order to control for potential off-target effects, the third shRPS6 experimental
group consisted of both shRPS6 constructs (S6#1 and S6#2) mixed together in halved,
proportionate amounts (0.2 µg of plasmid DNA/2 × 105 neurons of both constructs together). The
control group was transfected with shLuc, which targets the Renilla luciferase mRNA sequence
(5′-caaaggaaacggatgataa-3’) [26]. Validation of constructs and confirmation of successful RPS6
and TIF-IA knockdown was previously demonstrated [26; Slomnicki et al. In preparation].
Fluorescence microscopy (Zeiss Observer.Z1
inverted microscope) was used to obtain images from stained and fixed slides. Unfragmented
neurons were visualized with GFP immunostaining under a 10x objective lens. AxioVision
software was used to obtain black-and-white TIFF image files. Morphometric analysis of TIFF
Image Acquisition & Morphometric Analysis:
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images was carried out using the program Neuron Studio to trace axon paths [44]. Tracing files
generated by Neuron Studio were then analyzed in the MATLAB program (MathWorks) using
custom scripts that calculated the following key axonal parameters; total axon length, longest
axon path and number of branches
Nucleolar dispersion was assessed in shTIF-IA-transfected
neurons by assessing B23 immunostaining: control shLuc cells and cells with unsuccessful
shTIF-IA transfection presented with dense, red, brightly stained B23-positive foci indicative of
intact nucleoli; cells with successful shTIF-IA transfection lacked these dense B23-positive foci
and instead presented a more diffuse signal, indicating nucleolar dispersion. Cells not indicating
this nucleolar dispersion were not considered for imaging, tracing, or statistical analysis.
Quantification of shTIF-IA Inhibition:

Statistical analysis of the data involved using a two-way analysis of variance
(ANOVA) in conjunction with post hoc Fisher least significant difference tests.
Statistical Analysis:

EXPERIMENTAL GROUPS

Control	
  Group	
  -‐	
  
shLuc	
  
Vehicle	
  
Vehicle	
  +	
  BDNF	
  

shRPS6	
  Experiments	
  
Experimental	
  Group	
  #1	
  -‐	
   Experimental	
  Group	
  #2	
  -‐	
  
shRPS6.1	
  
shRPS6.2	
  
Vehicle	
  
Vehicle	
  
Vehicle	
  +	
  BDNF	
  
Vehicle	
  +	
  BDNF	
  

Experimental	
  Group	
  #3	
  -‐	
  
shRPS6.1	
  &	
  shRPS6.2	
  
Vehicle	
  
Vehicle	
  +	
  BDNF	
  

shTIF-‐IA	
  Experiments	
  
Control	
  Group	
  -‐	
  shLuc	
  

Experimental	
  Group	
  -‐	
  shTIF-‐IA	
  

Vehicle	
  
Vehicle	
  +	
  BDNF	
  

Vehicle	
  
Vehicle	
  +	
  BDNF	
  

RESULTS
First, we set out to determine the effects of transient shRNA knockdown of RPS6 on axon
morphology in rat hippocampal neuron cultures. Cultures of transiently transfected and
immunostained hippocampal neurons were fixed on slides, after which microscopic images were
taken using a GFP filter. Slides were coded to avoid experimenter bias, and axons were
consistently identified based on characteristic appearance and length [Figure 2]. Following
morphometric analysis with NeuronStudio and MATLAB software, we primarily focused on
three axonal parameters: total length, longest path, and number of branches.
For all control and experimental groups involving shRPS6, each group’s data represents the
mean ± S.E.M. for a total of at least 39 randomly selected neurons from two independent
experiments. Under baseline shLuc control conditions, axons demonstrated the following level of
growth and complexity: total axon length of 809 ±45 µm, longest axon path of 442 ±17 µm, and
6.78 ±0.67 axonal branches (all data presented as means ± S.E.M.) [Figures 3–5]. Upon BDNF
stimulation, the shLuc controls did not experience any significant neurotrophic boost of axon
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development compared to the baseline vehicle treatment: total axon length of 820 ±40 µm,
longest axon path of 473 ±20 µm, and 6.93 ±0.65 axonal branches (compared to baseline, all
three parameters not significant (NS), p > 0.05) [Figures 3-5].

Figure 2: Per the characteristic stages of neurite outgrowth for hippocampal neuron cultures, axons grow

much more quickly than dendrites; therefore, by DIV 3-4, their length generally makes axons easy to
distinguish from the shorter dendrites [23]. Thus, axons were identifiably distinct due their relatively sizable
lengths (as compared to smaller dendrites, which remained clustered closely around the cell body).

Of the three parameters, shRNA treatment only yielded statistically significant differences in
total axon length. Total length was reduced (albeit not drastically) in all shRPS6 experimental
groups except for the mixed construct group that was exposed to BDNF. Compared to the shLuc
control baseline, decreases were seen with mixed shRPS6 constructs (809 ±45 vs. 587 ±25 µm, p
< 0.001), shRPS6.1 (809 ±45 vs. 712 ±34 µm, p <0.05), and shRPS6.2 (809 ±45 vs. 680 ±33 µm,
p < 0.01); compared to the shLuc control with BDNF treatment, decreases were only seen with
shRPS6.1 (820 ±40 vs. 667 ±26 µm, p < 0.01) and shRPS6.2 (820 ±40 vs. 699 ±30 µm, p <
0.05), but not with mixed shRPS6 constructs (820 ±40 vs. 773 ±33 µm, NS) [Figure 3].
The results for longest path and number of branches did not indicate a consistent, significant
effect on axonal growth. Compared to the shLuc control baseline, the longest axon path was
decreased by mixed shRPS6 (442 ±17 vs. 370 ±15 µm, p < 0.01), but was unaffected by
shRPS6.1 (442 ±17 vs. 445 ±20 µm, NS) and shRPS6.2 (442 ±17 vs. 401 ±17 µm, NS);
compared the shLuc control with BDNF, longest axon path saw no effect with mixed shRPS6
(473 ±21 vs. 460 ±15 µm, NS), a decrease with shRPS6.1 (473 ±21 vs. 416 ±15 µm, p < 0.05),
and no effect with shRPS6.2 (473 ±21 vs. 443 ±18 µm, NS) [Figure 4]. Compared to the shLuc
control baseline, there was no effect on number of axonal branches with mixed shRPS6
(6.78 ±0.67 vs. 5.28 ±0.46, NS), shRPS6.1 (6.78 ±0.67 vs. 7.30 ±0.84, NS), or shRPS6.2
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(6.78 ±0.67 vs. 5.48 ±0.51, NS); compared to the shLuc control with BDNF, no effect was seen
for mixed shRPS6 (6.93 ±0.65 vs. 6.00 ±0.55, NS) or shRPS6.1 (6.93 ±0.65 vs. 6.13 ±0.57, NS),
but there was a decrease with shRPS6.2 (6.93 ±0.65 vs. 5.08 ±0.58, p < 0.05) [Figure 5].

Figure 3: Decrease in total
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Also, data from axonal experiments with shTIF-IA were examined by selecting specifically for
cells that demonstrated complete dispersion of the immuostained nucleolar marker B23, which
normally remains bound to nucleolar rRNA [18, 24]. By selecting for cells lacking distinct B23immunostained nuclei, we were able to ascertain exactly which cells had indeed experienced
shTIF-IA-mediated inhibition of pol I (and thus inhibition of de novo ribosome synthesis)
[Figure 6]. For all shLuc control groups in the shTIF-IA experiment, the data represents the
mean ± S.E.M. for a total of at least 39 randomly selected neurons from two independent
experiments. For all shTIF-IA experimental groups, the data represents the mean ± S.E.M. for a
total of at least 19 randomly selected neurons (among those that demonstrated B23 dispersion)
from two independent experiments.

Figure 6: Immunostaining with fluorescence microscopy allowed for selection of only those neurons that

demonstrated dispersion of the nucleolar phosphoprotein marker B23 and, thus, successful transfection by
shTIF-IA. In shLuc control cells, B23 staining resulted in small, dense, bright red granules (nucleoli) within a
larger, less dense, dull red region (nucleus). In shTIF-IA cells, B23 staining resulted in the absence of any of
the smaller, dense, bright red granules, thereby indicating nucleolar dispersion.
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Under baseline shLuc control conditions, axons demonstrated the following level of growth and
complexity: total axon length of 558 ±28 µm, longest axon path of 382 ±13 µm, and 4.18 ±0.45
axonal branches. Once again, BDNF treatment of shLuc controls failed to stimulate increased
growth compared to the baseline treatment: total axon length of 617 ±32 µm, longest axon path
of 408 ±25 µm, and 5.03 ±0.70 axonal branches (compared to baseline, all three parameters NS,
p > 0.05). Within baseline and BDNF treatment groups for each parameter, shTIF-IA did not
result in a statistically significant decrease for any parameters, with the only exception being a
decrease in branch ratio under BDNF treatment. Compared to the baseline shLuc control, shTIFIA treatment produced no change in total axon length under baseline conditions (558 ±28 vs.
589 ±29 µm, NS) or BDNF treatment (617 ±32 vs. 512 ±33 µm, NS) [Figure 7]; similarly,
longest axon path saw no change under baseline conditions (382 ±13 vs. 341 ±16 µm, NS) or
BDNF treatment (408 ±25 vs. 334 ±19 µm, NS) [Figure 8]; and the number of axonal branches
saw no change under baseline conditions (4.18 ±0.45 vs. 5.39 ±0.67 µm, NS) but decreased under
BDNF treatment (5.03 ±0.70 vs. 3.53 ±0.48 µm, p < 0.05) [Figure 9].

Total Length of Axon (µm)

All in all, these data indicate that shRPS6 did result in some significant decreases across all
parameters of axon growth, though overall the effects were relatively small and somewhat
inconsistent. The shTIF-IA produced essentially no significant decrease of axon growth, with the
only exception being the decrease in number of axonal branches under BDNF treatment.
Therefore, ribosomal biogenesis does not appear to be of major importance for axon growth at
least during early phases of this process.
Figure 7: No significant
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DISCUSSION
Initially, our hypothesis
held that shRNA-mediated
knockdown of TIF-IA and
RPS6 would result in a
decrease in axonal growth
due to direct inhibitory
effects on RNA pol I
activity and ribosomal
biogenesis. Ultimately,
however, our data indicate
that this hypothesis was
incorrect. Despite
antagonizing TIF-IA and
RPS6 – both of which play
important roles in ribosome
production – it appears that
pre-existing ribosomes are
sufficient for initial axonal
elongation [Figure 10].
However, the duration of this pre-existing ribosome supply would presumably be temporally
limited by the 6-day half-life of cytoplasmic ribosomes in the rat brain [9]. Thus, given more
time, ribosomal biogenesis inhibition would be expected to affect translation and axonal growth.
Aside from the hypothetical aspect regarding pre-existing ribosome supply, this schematic also
assumes the implicit necessity of protein synthesis for axonal growth during this stage; this
assumption is supported, however, by previously mentioned research showing that CHXmediated disruption of protein synthesis did indeed inhibit axonal growth during DIV 1-2 [42].
To be sure, shRNA knockdown of RPS6 did have a consistent, slight inhibitory effect on total
axonal length (but not on axon path or number of axonal branches) during the initiation phase of
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axonal development. Yet, while the decreases in total axon length for the shRPS6 constructs
were statistically significant, the effect was relatively small and not entirely consistent. These
results were corroborated by our experiments with shTIF-IA when B23 dispersion was taken into
consideration to assure shTIF-IA transfection and inhibition of rRNA transcription: the data did
not show a consistent, significant decrease in any of the three morphogenetic parameters. Taken
together, these complementary findings indicate that ribosome biogenesis and RNA pol I activity
are not important for axonal growth during the initiation phase of axonal development.
When interpreting these results, the slight inhibitory effect of shRPS6 could be attributed to the
role of RPS6 in ribosomal biogenesis, but could also potentially indicate that RPS6 has a noncanonical role other than being a structural and functional ribosome component. Once again,
future experiments would be necessary to obtain more evidence. The relatively modest
magnitude of the observed inhibitory effects, however, call into question the utility and
effectiveness of further experiments, such as with phosphomutants to block RPS6
phosphorylation.
Interestingly, there is no significant difference in the results for axon morphological parameters
between the baseline vehicle groups and the BDNF treatment groups. Despite the fact that the
vehicle treatment ideally represents baseline growth while BDNF treatment represents
neurotrophically-enhanced growth, it appears that BDNF is not significantly increasing axon
elongation during this stage. Given that the cells were fixed by DIV 3-4, this lack of BDNF
stimulation can likely be explained by the considerably robust level of axon growth around DIV
2 [23]; treatment with BDNF does little to increase this already robust, early growth.
Future research would include an investigation of the importance of ribosomal biogenesis and
pol I activity during later phases of axonal development. Presumably, both prolonged depletion
of ribosomes and nucleolar disruption would result in a more extreme deficit during later phases.
As such, it is probable that inhibition of ribosomal biogenesis (via ribosomal protein knockdown)
and inhibition of pol I activity (via TIF-IA knockdown) during later phases would result in even
more pronounced inhibition of axonal growth. Conducting experiments of this nature, however,
is difficult. Such experiments would require waiting until at least DIV 6-9, at which point the
axons grow to unwieldy lengths and present problems for tracing and morphometric analysis.
Within a broader context, this line of research aims to elucidate the role of ribosomal biogenesis
in healthy nervous system development at the cellular level. A relatively neglected field of study
has been the intrinsic mechanisms underlying neuronal development, with much emphasis being
placed instead on stimulated or altered growth and pathological growth problems. As such, this
research on rRNA and ribosomal production complements prior research on the importance of
biosynthesis of other macromolecules for normal neuron development during this initial growth
phase, including the processes of protein synthesis, lipid synthesis, and general transcription.
Additionally, it explores how dysfunctional ribosomal biogenesis or irregular neurite
morphogenesis may contribute to the pathogenesis of nervous system disorders. Generally, it is
expected that a lack of mature, functional ribosomes – which are responsible for protein
translation and, in turn, cell growth – would be lethal during embryonic development. However,
a recently investigated class of rare, genetic diseases of ribosome function and biogenesis –
referred to as “ribosomopathies” – has shown this expectation is not always true [19, 20]. Among
the causes for these ribosomopathies is a deficiency of ribosomal proteins: Diamond-Blackfan
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anemia is caused by congenital mutations in the genes for RPS19 and other ribosomal proteins,
and 5q– syndrome is brought on in part by a haploinsufficiency of RPS14 [20]. As a more
neurologically relevant example, one study has provided evidence that links a decline in protein
synthesis both to a decline in ribosome precursors and to high levels of oxidative damage to
ribosomal-associated RNA in the brains of patients with Alzheimer’s disease [21]. In addition,
mutations in the gene for RPL10 have been identified as the potential causal agents of the
cognitive malfunction seen in various cases of autism [22]. Finally, another recent study has
identified RPS15 as a mediator of the LRRK2-induced neurodegeneration seen in Parkinson’s
disease [25]. As the involvement of dysfunctional ribosomal biogenesis and neurite
morphogenesis in various diseases becomes increasingly apparent, our knowledge of these
cellular processes will continue to grow in importance.
In conclusion, neither shRPS6 nor shTIF-IA knockdown produced a consistent, meaningful
inhibitory effect on axon growth. It can be argued that the lack of a large inhibitory effect
following shRPS6 treatment is attributable to the fact that such shRNA knockdown is only able
to bring about an incomplete knockdown of RPS6, which is merely a single ribosomal
component. Consequently, the shTIF-IA experiment becomes increasingly important because it
avoids this issue: selecting for cells that only demonstrated complete B23 dispersion allowed for
the incorporation of only those cells whose nucleoli had been disrupted. Because nucleoli are
essentially brought into existence by their very “act of building a ribosome” [27], this lack of
visible nucleoli indicates that the entire process of ribosomal biogenesis has been disrupted.
Therefore, combining the results from these two experiments provides convincing evidence that
nucleolar RNA pol I activity (and the nucleolus-based process of ribosomal biogenesis) are of
minor importance to axon growth during this early phase of development. As an explanation for
this ability of axons to continue growing in the face of such inhibition, it is important to consider
the fact that shTIF-IA was shown to not disrupt translation specifically during the timeframe of
DIV 1-3 in which these experiments were conducted; previous experiments in which both
dendrite growth and translational capacity were diminished by shTIF-IA were conducted later
during DIV 6-9 [Slomnicki and Hetman, unpublished observations]. With this consideration in
mind, it appears that the various effects of ribosomal biogenesis inhibition on neurites can be
explained by differential modulation of protein synthesis, which appears to be essential for axon
growth [42]. Furthermore, considering the 6-day half-life of cytoplasmic ribosomes in the rat
brain and the robustness of cellular growth in this early stage [9, 23], the cell is able to maintain
protein synthesis and axon development despite experimental disruption of de novo ribosomal
biogenesis.
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